New Options in the Treatment of Hepatitis C (HCV): Economic and Clinical Considerations for Improved Patient Outcomes
A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 30, 2018 to June 30, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from AbbVie and Merck & Co

Description:
Hepatitis C virus (HCV) infection is the most common chronic blood borne infection in the United States. Approximately 75% to 85% of HCV-infected persons will progress to chronic HCV infection and are at risk for the development of extrahepatic manifestations, compensated and decompensated cirrhosis, and hepatocellular carcinoma. Approximately 3.5 million persons in the United States are chronically infected today. HCV-associated disease represents the leading indication in the United States for liver transplantation and the leading cause of hepatocellular cancer. The rapid evolution of therapeutic choices in HCV presents opportunities and substantial challenges to healthcare professionals. In light of evidence for the superior efficacy and adverse effect profiles of new and emerging therapies, health care professionals must select patients for treatment based on a thorough understanding of the clinical, economic, and societal ramifications of their decisions. This activity will help health care professionals implement practice changes and policies to improve patient outcomes in a cost-effective manner.

Upon Completion of this activity, participants will be able to:

  • Analyze clinical data on the mechanisms, efficacy and safety profiles of recently approved or late-stage antiviral agents in development for the treatment of HCV

  • Examine the role of HCV combination therapies in optimizing barriers to resistance

  • Identify emerging treatments for patients with HCV and comorbidities, complications, prior treatment experience, and varying HCV genotypes based on the latest guidelines and relevant clinical data

  • Apply clinical evidence and cost-effectiveness data relevant to managed care decision making on new HCV therapies

  • Incorporate institutional strategies that facilitate the appropriate use of newer and emerging HCV therapies
     

Faculty: Mark Sulkowski, MD
Professor of Medicine
Johns Hopkins University

Disclosure:

Dr. Sulkowski serves on an advisory board for AbbVie, Gilead, Merck and Trek. He serves as a consultant for AbbVie, Gilead, Merck and Trek. He has received research/grant support from AbbVie and Gilead. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from AbbVie and Merck & Co

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue